


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of treating a subject for a bacterial infection, comprising administering to a subject in need of treatment for a bacterial infection an effective amount of a compound represented by structural formula I-a':



or a pharmaceutically acceptable salt, solvate, or hydrate thereof,

wherein:

R1, R2, R3, and R4 are independently-H, halogen, -NO<sub>2</sub>, -CN, -(CO)OR<sup>b</sup>, -(CO)O(CO)R<sup>b</sup>, -(CS)OR<sup>b</sup>, -(CS)R<sup>b</sup>, -(SO)OR<sup>b</sup>, -SO<sub>3</sub>R<sup>b</sup>, -OSO<sub>3</sub>R<sup>b</sup>, -P(OR<sup>b</sup>)<sub>2</sub>, -(PO)(OR<sup>b</sup>)<sub>2</sub>, -O(PO)(OR<sup>b</sup>)<sub>2</sub>, -B(OR<sup>b</sup>)<sub>2</sub>, -(CO)NR<sup>c</sup>, -NR<sup>c</sup>, -NR<sup>d</sup>(CO)R<sup>b</sup>, -NR<sup>d</sup>(CO)OR<sup>b</sup>, -NR<sup>d</sup>(CO)NR<sup>c</sup>, -SO<sub>2</sub>NR<sup>c</sup>, -NR<sup>d</sup>SO<sub>2</sub>R<sup>b</sup>, or an optionally substituted aryl, aralkyl, heteroaryl, heteroaralkyl, C3 to C7 cycloalkyl, nonaromatic heterocycle, C1 to C4 alkyl, C1 to C4 alkoxy, C1 to C4 hydroxy alkyl, or C2 to C6 alkoxyalkyl;

wherein:

each R<sup>b</sup> and R<sup>d</sup> is independently -H or optionally substituted aryl, aralkyl, heteroaryl, heteroaralkyl, or C1 to C4 alkyl; and

each R<sup>c</sup> is independently -H or optionally substituted C1 to C4 alkyl, aryl, or aralkyl, or NR<sup>c</sup> is an optionally substituted nonaromatic heterocycle.


~~Ring A is a 5 or 6 membered cycloalkyl or cycloalkenyl group, optionally substituted with halogen or optionally halogenated C1-C3 alkyl or alkoxy;~~

~~X2 and X3 are each carbon, or one is nitrogen and the other is carbon; and~~

~~Rings B and C are optionally and independently substituted at any substitutable ring carbon, provided that one or two substitutable ring carbons in Rings B and C are substituted with an acidic group.~~

2. (Withdrawn) The method of Claim 1, wherein the subject is a human.

3. (Withdrawn) The method of Claim 2, wherein the infection is caused by a bacterium that expresses phosphoenolpyruvate:UDP-N-acetyl-D-glucosamine 1 carboxyvinyltransferase.
4. (Withdrawn) The method of Claim 2, wherein the infection is caused by a bacterium of a genus selected Allochromatium, Acinetobacter, Bacillus, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Citrobacter, Escherichia, Enterobacter, Enterococcus, Francisella, Haemophilus, Helicobacter, Klebsiella, Listeria, Moraxella, Mycobacterium, Neisseria, Proteus, Pseudomonas, Salmonella, Serratia, Shigella, Stenotrophomonas, Staphylococcus, Streptococcus, Synechococcus, Vibrio, and Yersina.
- 5 - 8. (Cancelled)
9. (Currently Amended) The method of Claim 8 1 wherein at least two of R1 to R4 are -H; and one or two of R1 to R4 are each independently -F, -Cl, -Br,  $-(CO)R^b$ ,  $-(CO)OR^b$ ,  $-(CO)NR^c$ ,  $-NR^c$ ,  $-NR^d(CO)R^b$ ,  $-NR^d(CO)OR^b$ ,  $-NR^d(CO)NR^c$ ,  $-NR^d(CO)PhNR^d(CO)R^b$ , or optionally substituted phenyl, benzyl, pyridyl, methylpyridyl, or optionally halogenated C1 to C4 alkyl or C1 to C4 alkoxy;
- 10 - 22. (Cancelled)
23. (Currently Amended) A compound represented by structural formula I-a':



or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein:

R1, R2, R3, and R4 are independently -H,  $-(CO)R^b$ ,  $-(CO)OR^b$ ,  $-(CO)O(CO)R^b$ ,  $-(CS)OR^b$ ,  $-(CS)R^b$ ,  $-(SO)OR^b$ ,  $-SO_3R^b$ ,  $-OSO_3R^b$ ,  $-P(OR^b)_2$ ,  $-(PO)(OR^b)_2$ ,  $-O(PO)(OR^b)_2$ ,  $-B(OR^b)_2$ ,  $-NR^c$ , -

$\text{NR}^d(\text{CO})\text{R}^b$ ,  $-\text{NR}^d(\text{CO})\text{OR}^b$ ,  $-\text{NR}^d(\text{CO})\text{NR}^c_2$ ,  $-\text{SO}_2\text{NR}^c_2$ ,  $-\text{NR}^d\text{SO}_2\text{R}^b$ , or an optionally substituted aryl, aralkyl, heteroaryl, heteroaralkyl, C3 to C7 cycloalkyl, or nonaromatic heterocycle;

wherein:

each  $\text{R}^b$  and  $\text{R}^d$  is independently -H or optionally substituted aryl, aralkyl, heteroaryl, heteroaralkyl, or C1 to C4 alkyl; and

each  $\text{R}^c$  is independently -H or optionally substituted C1 to C4 alkyl, aryl, or aralkyl, or  $\text{NR}^c_2$  is an optionally substituted nonaromatic heterocycle.


24. (Currently amended) The compound of Claim 23 wherein at least two of R1 to R4 are H; and

one or two of R1 to R4 are each independently  $-(\text{CO})\text{R}^b$ ,  $-(\text{CO})\text{OR}^b$ ,  $-(\text{CO})\text{NR}^c_2$ ,  $-\text{NR}^c_2$ ,  $\text{NR}^d(\text{CO})\text{R}^b$ ,  $-\text{NR}^d(\text{CO})\text{OR}^b$ ,  $-\text{NR}^d(\text{CO})\text{NR}^c_2$ ,  $-\text{NR}^d(\text{CO})\text{PhNR}^d(\text{CO})\text{R}^b$ , or optionally substituted phenyl, benzyl, pyridyl, or methylpyridyl;

wherein each  $\text{R}^b$ ,  $\text{R}^c$ , and  $\text{R}^d$  is independently -H, or optionally substituted C1 to C4 alkyl or phenyl, or each  $\text{NR}^c_2$  is an optionally substituted morpholinyl, piperidyl, or piperazyl.

25 - 28. (Canceled)


29. (Currently Amended) The compound of Claim ~~28~~ 23, wherein the compound is represented by one of the following structural formulas:




30 - 42. (Cancelled)

43. (New) The compound according to claim 23, wherein R1, R2, R3, and R4 are independently -H, -NR<sup>c</sup><sub>2</sub>, -NR<sup>d</sup>(CO)R<sup>b</sup>, -NR<sup>d</sup>(CO)OR<sup>b</sup>, -NR<sup>d</sup>(CO)NR<sup>c</sup><sub>2</sub>, -SO<sub>2</sub>NR<sup>c</sup><sub>2</sub>, or -NR<sup>d</sup>SO<sub>2</sub>R<sup>b</sup>.


44. (New) The compound according to claim 43, wherein the compound is selected from:




IX




XI




XIII



XXIII



XXV



XXVIII

and